Varian Uses AI to Usher in New Era of Cancer Therapy at ASTRO

Four years ago, Varian’s Applied Research Team, a group separate from its research and development unit, began looking at how to incorporate artificial intelligence into cancer therapy. The team’s hard work has resulted in the development of Ethos, an AI-driven holistic solution designed to increase the efficiency of radiotherapy. MD+DI spoke with Chris Toth, president of Varian Oncology Systems ahead of Ethos’ launch at the American Society for Radiation Oncology [ASTRO] annual meeting in Chicago held this week. Ethos is an Adaptive Intelligence solution. Toth told MD+DI, “Ethos therapy is the culmination of decades of the pursuit of how to personalize and adapt radiation therapy to every patient; everyday; in their anatomy; in any deprivation of the tumor or associated tissue, so that we can absolutely achieve what we want to in the context of maximizing the dose to the tumor and missing the healthy tissue.” The Palo Alto, CA-based company’s technology has CE mark and not yet been cleared in the U.S. The company said FDA clearance is pending. Ethos solves for an issue that has plagued cancer therapy treatments for years. “The challenge remains that patients get their treatments over a certain number of visits,” Toth said. “It could be five … 10 … 40 different visi...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news

Related Links:

CONCLUSION: Correlations within and among the instruments indicate EPIC bowel and urinary domains are measuring conceptually discrete components of health. These EPIC domains are valid, reliable and sensitive instruments to measure PRO among women undergoing pelvic radiation. PMID: 31104905 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Conclusions In the span of a very short time—less than a decade—robotic head and neck surgery has transformed the management of the head and neck cancer, and it seems clear that the future of treatment for these cancers lies in a multimodal approach in which TORS is likely to play an important role. Nevertheless, it is important to keep in mind that the current indications for TORS are limited and long-term data on the safety and oncological outcomes are needed to better understand the true role of TORS in treatment of head and neck cancer. Nonetheless, the emergence of ever more advanced robotic instruments i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Despite the implementation of IMRT, survivors of NPC still experience many physical symptoms that affect long-term QoL many years after treatment. Depression, anxiety, and fatigue remain common in long-term survivors and are highly correlated with QoL. PMID: 30191868 [PubMed - in process]
Source: Health Physics - Category: Physics Authors: Tags: Int J Radiat Oncol Biol Phys Source Type: research
Conclusion: Over recent years, radiotherapy techniques have been greatly developed which create various suitable conditions for the treatment of different cancers while sparing normal tissues. As the radiotherapy techniques developed, tumor covering and precision on dose delivery increased.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Radiation therapy (RT) is the mainstay of comprehensive treatments for breast cancer. The prognosis of these patients has been improved over the past decades as a result of early diagnosis with the use of new treatment modalities. Although this population is growing and the incidence of hypertension, valvular disease and cardiomyopathy has been increasing comparing to general population, the cardiovascular effect of cancer therapy has become one of the serious problems for the general health of cancer survivors [1,2].
Source: Physica Medica: European Journal of Medical Physics - Category: Journals (General) Authors: Tags: Original paper Source Type: research
The purpose of this study is to evaluate potential associations between increased platelets and oncologic outcomes in oropharyngeal cancer patients receiving concurrent chemoradiation. A total of 433 oropharyngeal cancer patients (OPC) treated with intensity‐modulated radiation therapy (IMRT) with concurrent chemotherapy between 2002 and 2012 were included under an approved IRB protocol. Complete blood count (CBC) data were extracted. Platelet and hemoglobin from the last phlebotomy (PLTpre‐chemoRT, Hgbpre‐chemoRT) before start of treatment were identified. Patients were risk‐stratified using Dahlstrom–Sturgi...
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Cancer Therapy and Prevention Source Type: research
Abstract The purpose of this study is to evaluate potential associations between increased platelets and oncologic outcomes in oropharyngeal cancer patients receiving concurrent chemoradiation. 433 oropharyngeal cancer patients (OPC) treated with intensity modulated radiation therapy (IMRT) with concurrent chemotherapy between 2002 and 2012 were included under an approved IRB protocol. Complete blood count (CBC) data was extracted. Platelet and hemoglobin from the last phlebotomy (PLTpre‐chemoRT, Hgbpre‐chemoRT) before start of treatment were identified. Patients were risk‐stratified using Dahlstrom‐Sturgis criteri...
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Cancer Therapy Source Type: research
Conclusion Overall quality of life scores were acceptable, but sexual functioning scores were suboptimal after IMRT for anal cancer.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: there is no increased risk of doing the lymph node dissection early on.   Dr. Eggener-CON   Basics Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients.  A Mayo study revealed no data showing therapeutic benefit in high risk patients.  For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit. Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Anatomy | Cancer | Cancer & Oncology | Cancer Therapy | Intensity-Modulated Radiation Therapy | Medical Devices | Mergers and Aquisitions | Radiation Therapy